Pharma company Everest Organics today said it has entered the US market with the initial supply order for Omiprazole API in the country.
Omiprazole API is a medication used in the treatment of gastroesophageal reflux disease, peptic ulcer disease and ZollingerEllison syndrome.
The company has tied up with a US based pharma firm and the same has resulted in the first trial order for the company, Everest Organics said in a BSE filing.
"We see excellent opportunity to drive increased sales and profitability by growing our sales to regulated market over the period of two to three years," Everest Organics MD Sri Kakarlapudi Srihari Raju said.
The entry into the US market is a significant step forward in strengthening the company's presence in developed market, he added.
The stock closed 2.15 per cent down at Rs 147.95 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
